Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

H. Tilly1, M. Gomes da Silva2, U. Vitolo3, A. Jack4, M. Meignan5, A. Lopez-Guillermo6, J. Walewski7, M. Andre8, P. W. Johnson9, M. Pfreundschuh10 & M. Ladetto11, on behalf of the ESMO Guidelines Committee* Centre Henri-Becquerel, Universite de Rouen, Rouen, France; Portuguese Institute of Oncology, Lisbon, Portugal; A.O. Citta della Salute e della Scienza di Torino, Turin, Italy; St James’s University Hospital, Leeds, UK; Henri Mondor University Hospital, Creteil, France; Hospital Clinic, Barcelona, Spain; Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warsaw, Poland; CHU Dinant-Godinne, UCL Namur, Yvoir, Belgium; Cancer Research UK, University of Southampton, Southampton, UK; Innere Medizin I, Universitat des Saarlandes, Hamburg, Germany; Divisione di Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

[1]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[2]  M. Martelli,et al.  Primary mediastinal large B-cell lymphoma. , 2008, Critical reviews in oncology/hematology.

[3]  C. Tzeng,et al.  Frequency of surveillance computed tomography in non‐Hodgkin lymphoma and the risk of secondary primary malignancies: A nationwide population‐based study , 2015, International journal of cancer.

[4]  T. Molina,et al.  Accurate Classification of Germinal Center B-Cell-Like/Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase-Multiplex Ligation-Dependent Probe Amplification Assay: A CALYM Study. , 2015, The Journal of molecular diagnostics : JMD.

[5]  M. Martelli,et al.  Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL) , 2015, Leukemia & lymphoma.

[6]  M. Aapro,et al.  Diffuse large B-cell lymphoma in the elderly: impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) expert position paper. , 2015, Journal of geriatric oncology.

[7]  R. Gascoyne,et al.  Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Béné,et al.  R-CHOP with or without Radiotherapy in Non-Bulky Limited-Stage Diffuse Large B Cell Lymphoma (DLBCL): Preliminary Results of the Prospective Randomized Phase III 02-03 Trial from the Lysa/Goelams Group , 2014 .

[9]  L. Staudt,et al.  A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator’s Choice in Relapsed/Refractory DLBCL , 2014 .

[10]  R. Gascoyne,et al.  Phase 2 Trial of Interim PET Scan-Tailored Therapy in Patients with Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC) , 2014 .

[11]  R. Gascoyne,et al.  Validation of a Prognostic Model to Assess the Risk of CNS Disease in Patients with Aggressive B-Cell Lymphoma , 2014 .

[12]  M. Yuen,et al.  Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Michael Hallek,et al.  Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Cerhan,et al.  Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  W. Wilson,et al.  Precision Treatment of Distinct Molecular Subtypes of Diffuse Large B-cell Lymphoma: Ascribing Treatment Based on the Molecular Phenotype , 2014, Clinical Cancer Research.

[16]  Scott E. Smith,et al.  Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. , 2014, Blood.

[17]  A. Intlekofer,et al.  Precision therapy for lymphoma—current state and future directions , 2014, Nature Reviews Clinical Oncology.

[18]  Bingshu E. Chen,et al.  Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Fisher,et al.  Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Michael L. Wang,et al.  Double hit lymphoma: the MD Anderson Cancer Center clinical experience , 2014, British journal of haematology.

[22]  Bernd Holleczek,et al.  Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. , 2014, The Lancet. Oncology.

[23]  J. Friedberg,et al.  Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. , 2014, The Lancet. Oncology.

[24]  D. Weisenburger,et al.  Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. , 2014, Journal of the National Cancer Institute. Monographs.

[25]  S. Opat,et al.  A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma , 2014, British Journal of Cancer.

[26]  F. Jardin.  Next generation sequencing and the management of diffuse large B-cell lymphoma: from whole exome analysis to targeted therapy. , 2014, Discovery medicine.

[27]  V. Pavone,et al.  Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. , 2014, The Lancet. Oncology.

[28]  N. Schmitz,et al.  Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. , 2014, The Lancet. Oncology.

[29]  T. Molina,et al.  Final results of a randomized phase II GELA/LYSA study of rituximab plus ACVBP or CHOP, using a PET-driven consolidation strategy, in patients with high-risk diffuse large B-cell lymphoma (DLBCL). , 2014 .

[30]  C. Rübe,et al.  Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Cerhan,et al.  Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  S. Montoto,et al.  HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era , 2014, AIDS.

[33]  Kai Fu,et al.  Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. , 2014, Blood.

[34]  J. Radford,et al.  De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  P. Gaulard,et al.  Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial , 2013, Haematologica.

[36]  J. Friedberg,et al.  Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. , 2013, The New England journal of medicine.

[37]  S. Barrington,et al.  PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. , 2013, Blood.

[38]  David Cunningham,et al.  Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles , 2013, The Lancet.

[39]  Catherine Thieblemont,et al.  Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[40]  B. Coiffier,et al.  Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  A. Rosenwald,et al.  MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. , 2013, Blood.

[42]  N. Schmitz,et al.  Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  A. Rosenwald,et al.  Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). , 2012, The Lancet. Oncology.

[44]  V. Pavone,et al.  Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. , 2012, Blood.

[45]  L. Staudt,et al.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  E. Schuuring,et al.  EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations , 2012, Leukemia.

[47]  B. Coiffier,et al.  Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. , 2012, The Lancet. Oncology.

[48]  K. Young,et al.  Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  R. Talamini,et al.  Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma. , 2012, The oncologist.

[50]  N. Schmitz,et al.  High-dose chemotherapy followed by allogeneic stem cell transplantation in high-risk relapsed and refractory aggressive non-Hodgkin lymphoma: Results of a prospective study of the German high-grade non-Hodgkin lymphoma study group. , 2012 .

[51]  M. Routbort,et al.  Prognostic value of MYC rearrangement in cases of B‐cell lymphoma, unclassifiable, with features intermediate between diffuse large B‐cell lymphoma and Burkitt lymphoma , 2012, Cancer.

[52]  R. Kridel,et al.  Prevention of CNS relapse in diffuse large B-cell lymphoma. , 2011, The Lancet. Oncology.

[53]  T. Molina,et al.  Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial , 2011, The Lancet.

[54]  M. Czuczman,et al.  Higher response to lenalidomide in relapsed/refractory diffuse large B‐cell lymphoma in nongerminal center B‐cell–like than in germinal center B‐cell–like phenotype , 2011, Cancer.

[55]  A. Rosenwald,et al.  The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  A. López-Guillermo,et al.  CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. , 2011, The Lancet. Oncology.

[57]  G. Salles,et al.  Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA , 2011, Haematologica.

[58]  G. Bisi,et al.  Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study. , 2011, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[59]  A. López-Guillermo,et al.  First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  K. Morris,et al.  Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma , 2011, Cancer.

[61]  N. Schmitz,et al.  Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORAL final analysis. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  J. Radford,et al.  R-CHOP14 versus R-CHOP21: Result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  J. Friedberg,et al.  Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  R. Gressin,et al.  First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: Preliminary results of the GOELAMS 075 prospective multicenter randomized trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  M. Ziepert,et al.  Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-Mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: Final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphona Study Group (DSHNHL). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  F. Jardin,et al.  Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. , 2011, The Lancet. Oncology.

[67]  M. Sant,et al.  Sant M, Allemani C, Tereanu C, et al; HAEMACARE Working Group. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724-3734 , 2011, Blood.

[68]  Michael Hummel,et al.  Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. , 2010, Blood.

[69]  R. Gressin,et al.  No Benefit of First-Line Rituximab (R) - High-Dose Therapy (R-HDT) Over R-CHOP14 for Young Adults with Diffuse Large B-Cell Lymphoma. Preliminary Results of the GOELAMS 075 Prospective Multicentre Randomized Trial , 2010 .

[70]  F. Berrino,et al.  Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. , 2010, Blood.

[71]  B. Coiffier,et al.  Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. , 2010, Blood.

[72]  N. Schmitz,et al.  Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  S. Barrans,et al.  Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  J. Szer,et al.  Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre‐transplant FDG‐PET scan following salvage chemotherapy , 2010, British journal of haematology.

[75]  Dirk Hasenclever,et al.  Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  T. Molina,et al.  R-CHOP14 Compared to R-CHOP21 in Elderly Patients with Diffuse Large B-Cell Lymphoma: Results of the Interim Analysis of the LNH03-6B GELA Study , 2009 .

[77]  C. Haioun,et al.  Interim 18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation – where do we stand? , 2009, Leukemia & lymphoma.

[78]  F. Cavalli,et al.  High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial , 2009, The Lancet.

[79]  R. Gascoyne,et al.  MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. , 2009, Blood.

[80]  A. Levis,et al.  Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study , 2009, Haematologica.

[81]  Kai Fu,et al.  A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy , 2009, Clinical Cancer Research.

[82]  L. Staudt,et al.  Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. , 2009, Blood.

[83]  M. Pfreundschuh,et al.  Hematology: Germinal center or nongerminal center DLBCL? , 2009, Nature Reviews Clinical Oncology.

[84]  L. Staudt,et al.  Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways , 2008, Proceedings of the National Academy of Sciences.

[85]  U. Jaeger,et al.  Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. , 2008, The Lancet. Oncology.

[86]  Markus Loeffler,et al.  Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). , 2008, The Lancet. Oncology.

[87]  C. Copie-Bergman,et al.  Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[88]  M. Boccadoro,et al.  Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) , 2007, Leukemia.

[89]  T. Molina,et al.  CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  Andrew Lister,et al.  Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  J. Baars,et al.  Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma. , 2006, International journal of radiation oncology, biology, physics.

[93]  J. Armitage,et al.  Is there a place for routine imaging for patients in complete remission from aggressive lymphoma? , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[94]  A. López-Guillermo,et al.  CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.

[95]  P. Zinzani,et al.  Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. , 2006, Haematologica.

[96]  T. Molina,et al.  ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. , 2005, The New England journal of medicine.

[97]  A. Zelenetz,et al.  Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. , 2004, Blood.

[98]  S. Horning,et al.  Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. , 2004, Blood.

[99]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[100]  T. Molina,et al.  Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. , 2003, Blood.

[101]  Adrian Wiestner,et al.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[102]  F. Cavalli,et al.  Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[104]  Pierre Morel,et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[105]  C. Dykewicz.  Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[106]  L. Kanz,et al.  Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[107]  T. Petrella,et al.  Changing trends in the incidence of non-Hodgkin's lymphoma in Europe. Biomed Study Group. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[108]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.